Clinical Trials Browser

OTHER × Endometrial Neoplasms × Paclitaxel × Clear all

NCT05039801 2026-04-15

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Phase 1 Recruiting

DermatologicGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

NCT05819892 2026-03-11

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Phase 1 Recruiting

Endometrial Neoplasms

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT03932409 2026-02-10

FIERCE

Phase 1 Active not recruiting

Endometrial Neoplasms

NCT05691010 2026-02-04

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

Phase EARLY_PHASE1 Recruiting

Endometrial Neoplasms

NCT06795009 2025-12-11

Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Phase 1 Recruiting

Uterine Neoplasms, Endometrial Neoplasms

NCT02730416 2025-07-29

Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer

Phase 2 Completed

Endometrial Neoplasms

NCT06977594 2025-06-24

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

Phase NA Not yet recruiting

Uterine Cervical Neoplasms, Drug Hypersensitivity, Ovarian Neoplasms, Endometrial Neoplasms

NCT04527900 2025-06-19

The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach

Phase 2 Terminated

Endometrial Neoplasms

NCT06023862 2025-06-15

DOVE

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT03603184 2025-05-09

AtTEnd

Phase 3 Completed

Neoplasms, Endometrial Neoplasms

NCT00513786 2025-03-28

Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma

Phase 2 Completed

38 enrolled 12 charts

Endometrial Neoplasms

NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Phase EARLY_PHASE1 Terminated

GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

NCT02630823 2025-01-03

MK-3475 Immunotherapy in Endometrial Carcinoma

Phase 1 Completed

10 enrolled 9 charts

Endometrial Neoplasms

NCT06751277 2024-12-27

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Phase 2 Not yet recruiting

Recurrence, Endometrial Neoplasms

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT06102252 2024-08-06

Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

Phase NA Not yet recruiting

Endometrial Neoplasms

NCT06363708 2024-04-12

Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer

Phase NA Not yet recruiting

Neoplasms, Endometrial Neoplasms

NCT01820858 2024-04-02

EC-01

Phase 3 Active not recruiting

Endometrial Neoplasms

NCT03189446 2024-03-08

Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer

Phase 2 Completed

39 enrolled 8 charts

Endometrial Neoplasms

NCT06297811 2024-03-07

Myeloprotection With Trilaciclib in Pan-cancer Population

Phase 2 Not yet recruiting

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03935256 2023-12-18

Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer

Phase 2 Unknown

Neoplasms, Endometrial Neoplasms

NCT04602117 2023-11-18

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Phase 1 Withdrawn

BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03503786 2023-11-13

MITO END-3

Phase 2 Unknown

Endometrial Neoplasms

NCT00411138 2023-10-11

PORTEC-3

Phase 3 Unknown

Endometrial Neoplasms

NCT02744898 2023-09-26

A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus

Phase 2 Completed

23 enrolled 9 charts

Endometrial Neoplasms

NCT02788708 2022-09-19

Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer

Phase 1 Completed

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05489848 2022-08-05

Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation

Phase 2/3 Not yet recruiting

Endometrial Neoplasms

NCT02549209 2022-03-02

Pembro/Carbo/Taxol in Endometrial Cancer

Phase 2 Completed

46 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03570437 2022-03-02

COPELIA

Phase 2 Unknown

GynecologicSarcoma

Carcinosarcoma, Neoplasms, Endometrial Neoplasms

NCT02269293 2021-04-23

Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers

Phase 1 Completed

Ovarian Neoplasms, Endometrial Neoplasms

NCT01523678 2019-07-10

Weekly Paclitaxel/Carboplatin With Neupogen in Gynaecological Cancers

Phase 2 Completed

Uterine Cervical Diseases, Uterine Cervical Neoplasms, Endocrine System Diseases, Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Diseases, Peritoneal Neoplasms, Urogenital Neoplasms, Uterine Diseases, Endometrial Neoplasms

NCT02069158 2019-05-21

IOSI-NDU-001

Phase 1 Completed

BreastGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT01256268 2017-08-30

Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids

Phase 1 Completed

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Endometrial Neoplasms

NCT00879359 2017-04-26

Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer

Phase 2 Completed

15 enrolled 8 charts

Endometrial Neoplasms

NCT00502203 2016-05-09

Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus

Phase 2 Completed

23 enrolled 5 charts

Uterine Neoplasms, Endometrial Neoplasms, Mixed Tumor, Mullerian

NCT00003334 2016-03-11

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Phase 2 Completed

GynecologicSarcoma

Fallopian Tube Neoplasms, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Sarcoma, Endometrial Stromal

NCT00334321 2015-10-05

Pelvic IMRT With Tomotherapy in Post-Hysterectomy Endometrial Cancer Patients

Phase 1 Completed

Endometrial Neoplasms

NCT00515073 2014-07-03

Papillary Serous Carcinoma of the Endometrium

Phase 2 Completed

30 enrolled 5 charts

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT00002949 2013-09-05

Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis

Phase 1 Completed

GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

NCT00006377 2013-06-18

Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer

Phase 2 Completed

Endometrial Neoplasms

NCT00373620 2006-09-08

A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients

Phase 2 Unknown

Endometrial Neoplasms